TL;DR
This systematic review examines the effectiveness of patient decision aids (PDAs) in lung cancer consultations, finding they generally improve patient knowledge, reduce anxiety, and enhance decision-making. While no single PDA emerged as superior, the review highlights the importance of clear communication and patient involvement in treatment choices.
What Problem Does This Paper Address?
Lung cancer is a devastating diagnosis with complex treatment options. Patients often struggle to understand their disease, treatment modalities, and potential side effects, leading to anxiety and uncertainty. This lack of clear information can hinder effective decision-making and negatively impact their quality of life. The paper addresses the need for tools that can bridge this information gap and empower patients to actively participate in their care decisions. Specifically, it investigates how Patient Decision Aids (PDAs) are implemented and their impact on lung cancer patients during consultations.
Methods
The researchers conducted a systematic review following PRISMA guidelines. They searched three major databases (Embase, PubMed, and Scopus) for studies published up to July 1, 2022. The search terms included "lung cancer care," "non-small cell lung cancer," "decision aid," "patient decision aid," "shared decision making," and "NSCLC." They specifically included quantitative research studies that applied a PDA in a patient-clinician interaction, evaluated its impact on patient outcomes (like anxiety, coping, and depression), and involved lung cancer patients. Qualitative studies, reviews, and theoretical articles were excluded. The quality of the included studies was assessed using the Cochrane risk of bias tool.
Datasets
Not discussed in the paper. This paper is a systematic review of existing literature, not an empirical study that collected or analyzed new datasets.
Key Insights and Ideas
- PDAs are generally beneficial: The review consistently shows that PDAs positively impact various aspects of the patient experience, from understanding their illness to feeling more confident in their choices.
- No one-size-fits-all solution: While PDAs are effective, the review found no single type of PDA that stands out as universally superior. This suggests that the best approach might be tailored to individual patient needs and preferences.
- Beyond just information: PDAs seem to work by not only providing information but also by fostering a sense of empowerment and facilitating a more collaborative decision-making process between patients and clinicians.
- Anxiety reduction is a key win: A significant finding is the consistent reduction in patient anxiety after using PDAs, which is crucial given the high-stress nature of a lung cancer diagnosis.
- The importance of communication: The review underscores that effective patient-clinician communication is a cornerstone for reducing decisional conflict and improving treatment adherence.
Key Results
The systematic review included 10 studies. The main outcomes observed were:
- Decision-making: Nine studies demonstrated improvements in decision-making processes, including reduced decisional conflict, increased satisfaction, and better alignment with patient preferences.
- Patient Knowledge: Six studies showed that PDAs improved patients' understanding of their disease characteristics and treatment options.
- Anxiety: Two studies reported a decrease in patient anxiety after using PDAs.
- Other Variables: Six studies reported improvements in other areas such as quality of life, cognitive function, information recall, and tool acceptability.
Limitations and Future Work
The authors acknowledge several limitations:
- Database Scope: While three databases were used, a more comprehensive search might have captured additional relevant studies.
- Timeframe: Focusing on a more recent timeframe could provide insights into the latest PDA tools.
- Qualitative Data: The review primarily focused on quantitative studies; incorporating qualitative research could offer a richer understanding of patient perspectives.
- Limited Novel Therapies: Only one study included PDAs for immunotherapy and targeted therapies, highlighting a gap given the evolving treatment landscape.
Future work suggested includes:
- Utilizing alternative search strategies to explore a wider range of lung cancer-specific outcomes.
- Engaging with experts in oncology, patient decision-making, and health communication to identify less accessible literature.
- Developing guidelines for future research to promote patient-centered PDAs.
- Conducting meta-analyses to better assess the effectiveness of PDAs.
- Creating new PDAs that address novel treatment choices in lung cancer.
Summary updated